Pricing Log in Create free account

SeaStar Medical Holding Corporation (ICU) vs Lipocine Inc. (LPCN)

SeaStar Medical Holding Corporation and Lipocine Inc. are both Biotechnology companies. SeaStar Medical Holding Corporation and Lipocine Inc. are of similar size ($13.9M and $13.5M). SeaStar Medical Holding Corporation grew revenue faster over the last twelve months: 123.6% against −63.5%. Lipocine Inc. has the higher net margin (−755.1% vs −795.5%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Lipocine Inc. leads on 11 and SeaStar Medical Holding Corporation on 4.

Valuation

Metric ICU LPCN Biotechnology median
P/E n/m n/m 8.50
P/S 6.99 7.75 9.71
P/B 2.79 0.56 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.64 0.64
EV/Sales 4.42 (5.21) 9.21
Earnings yield (133.45%) (126.35%) (33.15%)
Free cash flow yield (114.43%) (92.84%) (25.50%)

Profitability

Metric ICU LPCN Biotechnology median
Gross margin 92.64% 100.00% 65.16%
Operating margin (816.75%) (800.80%) 0.00%
Net margin (795.50%) (755.11%) 0.00%
Free cash flow margin (799.36%) (713.02%) 0.00%
Return on equity (356.87%) (60.94%) (56.36%)
Return on assets (160.02%) (55.89%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ICU LPCN Biotechnology median
Revenue growth (TTM) 123.63% (63.48%) 6.02%
EPS growth (last fiscal year) 91.16% (93,988.89%) 30.26%
Revenue growth, 5-year CAGR — 64.32% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ICU LPCN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.89 11.48 4.72
Net debt to EBITDA 0.99 1.42 0.96

Dividend

Metric ICU LPCN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ICU LPCN Biotechnology median
Market cap 13.48m 13.85m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack